Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients

• DOI: 10.1007/s00259-022-05721-z
• Publication Date: 2022-03-07T10:05:45Z
• Authors: Elisa Perry; Arpit Talwar; Sanjana Sharma; Daisy O’Connor; Lih-Ming Wong; Kim Taubman; Tom R. Sutherland
• Keywords: Male; Incidence; Lysine; 610; Prostatic Neoplasms; Kidney Neoplasms; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Positron Emission Tomography Computed Tomography; Humans; Urea; Original Article; Carcinoma, Renal Cell

With increasing use of PSMA PET/CT in the staging and restaging prostate cancer (PCa), identification non-prostate tumours (NPCaT) has become an clinical dilemma. Atypical presentations expression NPCaT are not well established. Understanding normal abnormal distribution is essential preparing clinically relevant reports guiding multidisciplinary discussion decisions.Retrospective review 1445 consecutive 18F-DCFPyL studies by experienced radiologists nuclear medicine physicians. Lesions indeterminate for PCa were identified. Correlation was made with patient records, biopsy results, dedicated imaging. then categorized into four groups: 1. Confirmed cancer, metastases, 2. 3. Benign, 4. Indeterminate lesions.68/1445 patients had lesions atypical metastases. These comprised 8/68 (11.8%) 17/68 (25.0%) NPCaT, 29/68 (42.6%) indeterminate, 14/68 (20.6%) benign. In context entire cohort, these adjusted to 8/1445 (0.6%), 17/1445 (1.2%), 29/1445 (2.0%), 14/1445 (1.0%) respectively. exception Renal Cell Carcinoma (RCC), demonstrated no or low expression. A similar trend also observed benign lesions. Conversely, most metastases intermediate high expression.18F-DCFPyL detection low. demonstrating exclusively aside from RCC, detected organs background